153 related articles for article (PubMed ID: 33733758)
1. Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor.
Zhang H; Peng X; Dai Y; Shao J; Ji Y; Sun Y; Liu B; Cheng X; Ai J; Duan W
J Med Chem; 2021 Apr; 64(7):3956-3975. PubMed ID: 33733758
[TBL] [Abstract][Full Text] [Related]
2. 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors.
Tan L; Zhang Z; Gao D; Luo J; Tu ZC; Li Z; Peng L; Ren X; Ding K
J Med Chem; 2016 Jul; 59(14):6807-25. PubMed ID: 27379978
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a 1,6-naphthyridin-4-one-based AXL inhibitor with improved pharmacokinetics and enhanced in vivo antitumor efficacy.
Lan Y; Peng X; Ji Y; Su Y; Duan W; Ai J; Zhang H
Eur J Med Chem; 2024 Feb; 265():116045. PubMed ID: 38128234
[TBL] [Abstract][Full Text] [Related]
4. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 10
Zhan Z; Ji Y; Su H; Fang C; Peng X; Liu Q; Dai Y; Lin D; Xu Y; Ai J; Duan W
J Med Chem; 2023 Jan; 66(1):220-234. PubMed ID: 36524812
[TBL] [Abstract][Full Text] [Related]
6. Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.
Xu D; Sun D; Wang W; Peng X; Zhan Z; Ji Y; Shen Y; Geng M; Ai J; Duan W
Eur J Med Chem; 2021 Aug; 220():113497. PubMed ID: 33957388
[TBL] [Abstract][Full Text] [Related]
7. Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling.
Park JS; Lee C; Kim HK; Kim D; Son JB; Ko E; Cho JH; Kim ND; Nan HY; Kim CY; Yoon S; Lee SH; Choi HG
Oncotarget; 2016 Dec; 7(50):83308-83318. PubMed ID: 27829217
[TBL] [Abstract][Full Text] [Related]
8. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors.
Chan S; Zhang Y; Wang J; Yu Q; Peng X; Zou J; Zhou L; Tan L; Duan Y; Zhou Y; Hur H; Ai J; Wang Z; Ren X; Zhang Z; Ding K
J Med Chem; 2022 Nov; 65(22):15374-15390. PubMed ID: 36358010
[TBL] [Abstract][Full Text] [Related]
11. Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy.
Goff D; Zhang J; Heckrodt T; Yu J; Ding P; Singh R; Holland S; Li W; Irving M
Bioorg Med Chem Lett; 2017 Aug; 27(16):3766-3771. PubMed ID: 28711351
[TBL] [Abstract][Full Text] [Related]
12. AXL regulates mesothelioma proliferation and invasiveness.
Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA
Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014
[TBL] [Abstract][Full Text] [Related]
13. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
Taverna JA; Hung CN; DeArmond DT; Chen M; Lin CL; Osmulski PA; Gaczynska ME; Wang CM; Lucio ND; Chou CW; Chen CL; Nazarullah A; Lampkin SR; Qiu L; Bearss DJ; Warner S; Whatcott CJ; Mouritsen L; Wade M; Weitman S; Mesa RA; Kirma NB; Chao WT; Huang TH
Cancer Res; 2020 Apr; 80(7):1551-1563. PubMed ID: 31992541
[TBL] [Abstract][Full Text] [Related]
14. Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.
Ng PS; Foo K; Sim S; Wang G; Huang C; Tan LH; Poulsen A; Liu B; Tee DHY; Ahmad NHB; Wang S; Ke Z; Lee MA; Kwek ZP; Joy J; Anantharajan J; Baburajendran N; Pendharkar V; Manoharan V; Vuddagiri S; Sangthongpitag K; Hill J; Keller TH; Hung AW
Bioorg Med Chem; 2021 Nov; 49():116437. PubMed ID: 34600239
[TBL] [Abstract][Full Text] [Related]
15. HGF-induced formation of the MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion.
Li W; Xiong X; Abdalla A; Alejo S; Zhu L; Lu F; Sun H
J Biol Chem; 2018 Oct; 293(40):15397-15418. PubMed ID: 30108175
[TBL] [Abstract][Full Text] [Related]
16. AXL kinase as a novel target for cancer therapy.
Wu X; Liu X; Koul S; Lee CY; Zhang Z; Halmos B
Oncotarget; 2014 Oct; 5(20):9546-63. PubMed ID: 25337673
[TBL] [Abstract][Full Text] [Related]
17. AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.
Zhu C; Wei Y; Wei X
Mol Cancer; 2019 Nov; 18(1):153. PubMed ID: 31684958
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo.
Onken J; Torka R; Korsing S; Radke J; Krementeskaia I; Nieminen M; Bai X; Ullrich A; Heppner F; Vajkoczy P
Oncotarget; 2016 Mar; 7(9):9876-89. PubMed ID: 26848524
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies.
Kariolis MS; Miao YR; Diep A; Nash SE; Olcina MM; Jiang D; Jones DS; Kapur S; Mathews II; Koong AC; Rankin EB; Cochran JR; Giaccia AJ
J Clin Invest; 2017 Jan; 127(1):183-198. PubMed ID: 27893463
[TBL] [Abstract][Full Text] [Related]
20. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA
Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
